Irritable bowel syndrome. Irritable bowel syndrome with diarrhoea
Conditions
Interventions
placebo 3 times daily
Intervention 1: Mesalamine 800 mg three times a day for 2 months. Intervention 2: placebo 3 times daily. Intervention 3: Colonoscopy and biopsy at baseline and end of treatment.
Treatment - Drugs
Diagnosis
Mesalamine 800 mg three times a day for 2 months
Colonoscopy and biopsy at baseline and end of treatment
Sponsors
Digestive and Liver Disease Research Center, Shariati Hospital
Rossen Darman company
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- Consent to participate in the study and signing the consent form; 2 - being at the age of 18 years and older. Exclusion criteria: 1 - Pregnancy or breast feeding; 2 - not using appropriate contraceptive methods; 3 - the use of NSAIDs; 4 - Use of corticosteroids, antibiotics, mast cell stabilizing drugs; 5- Large abdominal surgery; 6 - Celiac disease (positive Anti TTG and Anti Endomysial Ab); 7 - specific allergic diseases like asthma (positive family and personal history and positive Anti IGE); 8 - organic or psychological disorders characterized by history and specific laboratory tests; 9 - lack of cooperation in implementation of the Study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mucosal biomarkers. Timepoint: Before the study and at the end of study. Method of measurement: Sample Pathology.;Symptoms (diarrhea - abdominal pain - bloating - urgency - the number of bowel movements per day). Timepoint: Baseline, during and at the end of intervention. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of mast cell. Timepoint: Beginning and end of the intervention. Method of measurement: Sample pathology.;IHC CD117. Timepoint: Beginning and end of the intervention. Method of measurement: Sample pathology.;Gastrointestinal side effects (diarrhea - bloating - constipation). Timepoint: Initially, during and end of treatment. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Homayon Vahedi
Research Center for Gastroenterology and Liver
Outcome results
None listed